Esperion Therapeutics, Inc. (NASDAQ:ESPR) Stock Holdings Lifted by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 18.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,454,216 shares of the biopharmaceutical company’s stock after purchasing an additional 385,099 shares during the period. JPMorgan Chase & Co. owned 1.25% of Esperion Therapeutics worth $5,399,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ESPR. Public Employees Retirement System of Ohio bought a new stake in shares of Esperion Therapeutics during the third quarter valued at approximately $606,000. Wellington Management Group LLP boosted its position in shares of Esperion Therapeutics by 66.8% during the third quarter. Wellington Management Group LLP now owns 602,936 shares of the biopharmaceutical company’s stock worth $995,000 after buying an additional 241,512 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Esperion Therapeutics by 31.0% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 932,008 shares of the biopharmaceutical company’s stock valued at $2,050,000 after acquiring an additional 220,730 shares during the last quarter. Sigma Planning Corp raised its stake in Esperion Therapeutics by 1,455.8% in the 4th quarter. Sigma Planning Corp now owns 190,441 shares of the biopharmaceutical company’s stock valued at $419,000 after acquiring an additional 178,200 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of Esperion Therapeutics by 4.1% during the third quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock worth $7,148,000 after buying an additional 171,609 shares in the last quarter. 47.39% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a research report on Thursday, March 20th. The Goldman Sachs Group lowered their target price on shares of Esperion Therapeutics from $4.00 to $3.00 and set a “neutral” rating for the company in a research note on Thursday. JMP Securities reiterated a “market outperform” rating and set a $4.00 target price (down previously from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. Finally, Needham & Company LLC restated a “buy” rating and set a $5.00 price objective on shares of Esperion Therapeutics in a report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $6.42.

Esperion Therapeutics Stock Down 1.4 %

Shares of NASDAQ:ESPR opened at $0.95 on Friday. The company has a 50-day moving average price of $1.49 and a two-hundred day moving average price of $1.99. Esperion Therapeutics, Inc. has a twelve month low of $0.93 and a twelve month high of $3.94. The firm has a market capitalization of $187.96 million, a PE ratio of -1.48 and a beta of 0.86.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.